GGrantIndex
← Search

Healthy and At-Risk Populations

$32,230P30FY2017CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

The Healthy and At-Risk Populations program (HARP) has 34 core members representing four schools and 13 departments in total. During the current funding year, cancer-related funding for this program totaled $20.8M in total costs. Of this amount, peer-reviewed funding totaled $13.5M in total costs, including $3.4M from the National Cancer Institute. As with other programs, JCCC fosters a number of interactive activities and shared resources that support investigators in HARP. During the current grant cycle, funds from the JCCC in the form of the CCSG Developmental Funds, institutional support and philanthropic gifts to HARP total $2,043,085. These funds supported seed grants, program area leadership support, as well as the annual disparities symposium hosted by HARP in the community. The HARP program is highly interactive, with 15% of its publications reflecting intra-programmatic efforts and 11 % reporting inter-programmatic collaborations. 178 (28%) appeared in high-impact journals. Accruals to prevention trials totaled 1,186, screening 1,021, early detection/diagnostic 1,151, epidemiologic/obs/outcome 1,426, correlative 113. The goals of the HARP are to advance understanding of cancer risk and protective factors and to identify strategies to make the latest cancer prevention knowledge and technologies accessible to the population at large. HARP research spans four broad focus areas: 1. cancer risk and protective factors/etiology, 2. primary prevention, 3. screening/early detection, 4. infrastructure projects supporting community engagement. Two major themes characterize the research of this program: cancer disparities and translational research (mainly T3 and T4). These themes are not mutually exclusive, and in fact most projects in the program incorporate both. Our cancer disparities research focuses on cancer prevention and control interventions to mitigate disparities in low-income, ethnic minority and other socially and medically underserved populations in Los Angeles and beyond and has brought recognition to UCLA as one of the premier cancer disparities research programs in the nation.

View original record on NIH RePORTER →